Literature DB >> 20189486

Criteria for inclusion of vaccinations in public programmes.

Hans Houweling1, Marcel Verweij, E Joost Ruitenberg.   

Abstract

As more and more new vaccines are developed and brought to the market, governments have to make decisions about which vaccinations to include in public programmes. This paper describes the experience in the Netherlands in developing a framework for assessing whether a vaccination should be included in the National Immunization Programme (NIP). Bearing in mind the public nature, the factors that determine a vaccine's suitability for inclusion in a communal vaccination programme have been translated into seven selection criteria, grouped under five thematic headings: seriousness and extent of the disease burden, effectiveness and safety of the vaccination, acceptability of the vaccination, efficiency of the vaccination, and priority of the vaccination. The seven criteria and the explanation of them provide a framework for the systematic examination of arguments for and against the inclusion and prioritisation of particular vaccinations. As an illustration, the vaccinations currently provided in the Netherlands through public programmes as well as 23 'candidate' vaccinations are assessed against the seven criteria. The proposed assessment framework including the selection criteria can take full account of the values and specificities as they may differ between situations and countries; the transparency of the approach may help to clarify which elements of the assessment are pivotal in specific situations. Using the criteria furthers a trustworthy, transparent and accountable process of decision-making about inclusion of new vaccinations in public vaccination programmes and may help to retain public confidence. Copyright 2010 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 20189486     DOI: 10.1016/j.vaccine.2010.02.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  [Health Technology Assessment (HTA) of the introduction of influenza vaccination for Italian children with Fluenz Tetra®].

Authors:  Sara Boccalini; Elena Pariani; Giovanna Elisa Calabrò; Chiara DE Waure; Donatella Panatto; Daniela Amicizia; Piero Luigi Lai; Caterina Rizzo; Emanuele Amodio; Francesco Vitale; Alessandra Casuccio; Maria Luisa DI Pietro; Cristina Galli; Laura Bubba; Laura Pellegrinelli; Leonardo Villani; Floriana D'Ambrosio; Marta Caminiti; Elisa Lorenzini; Paola Fioretti; Rosanna Tindara Micale; Davide Frumento; Elisa Cantova; Flavio Parente; Giacomo Trento; Sara Sottile; Andrea Pugliese; Massimiliano Alberto Biamonte; Duccio Giorgetti; Marco Menicacci; Antonio D'Anna; Claudia Ammoscato; Emanuele LA Gatta; Angela Bechini; Paolo Bonanni
Journal:  J Prev Med Hyg       Date:  2021-09-10

2.  Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands.

Authors:  Alies van Lier; Albert Jan van Hoek; Wim Opstelten; Hein J Boot; Hester E de Melker
Journal:  BMC Health Serv Res       Date:  2010-08-13       Impact factor: 2.655

3.  Comparatively low attendance during Human Papillomavirus catch-up vaccination among teenage girls in the Netherlands: Insights from a behavioral survey among parents.

Authors:  Giedre Gefenaite; Marieke Smit; Hans W Nijman; Adriana Tami; Ingrid H Drijfhout; Astrid Pascal; Maarten J Postma; Bert A Wolters; Johannes J M van Delden; Jan C Wilschut; Eelko Hak
Journal:  BMC Public Health       Date:  2012-07-02       Impact factor: 3.295

4.  Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster.

Authors:  Alies van Lier; Anna Lugnér; Wim Opstelten; Petra Jochemsen; Jacco Wallinga; François Schellevis; Elisabeth Sanders; Hester de Melker; Michiel van Boven
Journal:  EBioMedicine       Date:  2015-08-08       Impact factor: 8.143

5.  What criteria do decision makers in Thailand use to set priorities for vaccine introduction?

Authors:  Siriporn Pooripussarakul; Arthorn Riewpaiboon; David Bishai; Charung Muangchana; Sripen Tantivess
Journal:  BMC Public Health       Date:  2016-08-02       Impact factor: 3.295

6.  Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.

Authors:  Bernhard Ultsch; Oliver Damm; Philippe Beutels; Joke Bilcke; Bernd Brüggenjürgen; Andreas Gerber-Grote; Wolfgang Greiner; Germaine Hanquet; Raymond Hutubessy; Mark Jit; Mirjam Knol; Rüdiger von Kries; Alexander Kuhlmann; Daniel Levy-Bruhl; Matthias Perleth; Maarten Postma; Heini Salo; Uwe Siebert; Jürgen Wasem; Ole Wichmann
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

7.  Intention to vaccinate universally against varicella, rotavirus gastroenteritis, meningococcal B disease and seasonal influenza among parents in the Netherlands: an internet survey.

Authors:  Alies van Lier; José A Ferreira; Liesbeth Mollema; Elisabeth A M Sanders; Hester E de Melker
Journal:  BMC Res Notes       Date:  2017-12-04

8.  Italian Physicians' Opinions on Rotavirus Vaccine Implementation.

Authors:  Valentin Mita; Michele Arigliani; Laura Zaratti; Raffaele Arigliani; Elisabetta Franco
Journal:  Pathogens       Date:  2017-11-03

9.  Disease burden of varicella versus other vaccine-preventable diseases before introduction of vaccination into the national immunisation programme in the Netherlands.

Authors:  Alies van Lier; Brechje de Gier; Scott A McDonald; Marie-Josée J Mangen; Maarten van Wijhe; Elisabeth A M Sanders; Mirjam E Kretzschmar; Hans van Vliet; Hester E de Melker
Journal:  Euro Surveill       Date:  2019-05

10.  Negative attitude and low intention to vaccinate universally against varicella among public health professionals and parents in the Netherlands: two internet surveys.

Authors:  Alies van Lier; Alma Tostmann; Irene A Harmsen; Hester E de Melker; Jeannine L A Hautvast; Wilhelmina L M Ruijs
Journal:  BMC Infect Dis       Date:  2016-03-15       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.